文献速递结核与非结核分枝杆菌艾滋病与性传播感染

贝达喹啉在HIV阳性和阴性耐利福平结核病年长儿童及青少年中的药代动力学与安全性

Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2022-01-01

这项观察性队列研究在南非接受常规治疗的6-17岁耐多药/耐利福平结核病儿童中评估贝达喹啉药代动力学与安全性,15例中仅3例(20%)达到成人暴露参考值,总体暴露低于目标;27例不良事件至少可能与贝达喹啉相关,无因此停药,2例严重(关节炎和关节痛),2例轻度QT间期延长。

要点

  • 贝达喹啉在6-17岁儿童中总体暴露低于成人参考值,仅3例(20%)达到AUC参考值。
  • 贝达喹啉生物利用度为成人的57%,可能因给药相对进食延迟所致。
  • 评估剂量安全性可接受,无因不良事件停用贝达喹啉,2例严重不良事件为关节炎和关节痛。

核心结论

  • 6岁及以上儿童接受评估剂量的贝达喹啉是安全的,但血浆浓度略低于接受推荐剂量的成人,可能由于给药相对进食延迟所致。

研究设计与样本

  • 观察性队列研究,纳入南非接受常规耐多药/耐利福平结核病治疗的6-17岁儿童,进行半密集药代动力学采样,量化贝达喹啉及M2代谢物血浆浓度并采用非线性混合效应模型,使用成人贝达喹啉药代动力学预设模型描述儿童数据。
  • 共纳入15例儿童(3例HIV阳性),中位年龄13.3岁(范围6.5-16.3)。
  • 暴露参考值为187 µg·h/mL,即成人治疗第24周贝达喹啉周AUC中位数。
  • 安全性通过每月临床、血液和心电图监测评估,并描述治疗结局。

主要发现

  • 贝达喹啉药代动力学模型经异速增长调整清除率和分布容积,以儿童中位体重为中心。
  • 贝达喹啉生物利用度为成人的57%。
  • 总体贝达喹啉暴露低于目标,仅3例(20%)儿童达到AUC参考值。
  • 10例儿童发生27例至少可能与贝达喹啉相关的不良事件,无不良事件导致贝达喹啉停用。
  • 2例不良事件(关节炎和关节痛)被认为严重,2例儿童出现轻度Fridericia公式校正QT间期延长。

关键数值与推荐

  • 暴露参考值为187 µg·h/mL(成人第24周贝达喹啉周AUC中位数),仅3例(20%)儿童达到该参考值。
  • 贝达喹啉生物利用度为成人的57%。
  • 10例儿童发生27例至少可能与贝达喹啉相关的不良事件,无导致停药的不良事件。
  • 2例不良事件(关节炎和关节痛)被认为严重;2例儿童出现轻度Fridericia公式校正QT间期延长。

临床怎么用

  • 原文结论指出6岁及以上儿童接受评估剂量的贝达喹啉是安全的,但血浆浓度略低于接受推荐剂量的成人,可能由于给药相对进食延迟所致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pharmacokinetic data for bedaquiline in children are limited. We described the pharmacokinetics and safety of bedaquiline in South African children and adolescents receiving treatment for multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB) in routine care. METHODS: In this observational cohort study, children aged 6-17 years receiving bedaquiline at recommended doses as part of MDR/RR-TB treatment underwent semi-intensive pharmacokinetic sampling. Bedaquiline and the M2 metabolite plasma concentrations were quantified, and nonlinear mixed-effects modeling performed. Pediatric data were described using a pre-established model of bedaquiline pharmacokinetics in adults. The exposure reference was 187 µg ⋅ h/mL, the median weekly area under the curve (AUC) of adults at week 24 of treatment with bedaquiline. Safety was assessed through monthly clinical, blood and electrocardiogram monitoring, and treatment outcomes described. RESULTS: Fifteen children (3 human immunodeficiency virus [HIV]-positive) with median age 13.3 years (range 6.5-16.3) were included. A bedaquiline pharmacokinetic model was adapted to be allometrically scaled in clearance and volume, centered in the median child population weight. Bedaquiline bioavailability was 57% of that in adults. Overall bedaquiline exposures were below target, and AUC reference attainment was achieved in only 3 (20%) children. Ten children experienced 27 adverse events at least possibly related to bedaquiline; no adverse events led to bedaquiline withdrawal. Two adverse events (arthritis and arthralgia) were considered severe, and 2 children had mild QT interval corrected for heart rate using Fridericia's formula (QT) prolongation. CONCLUSIONS: The evaluated doses of bedaquiline in children ≥ 6 years of age were safe but achieved slightly lower plasma concentrations compared to adults receiving the recommended dose, possibly due to delayed food intake relative to bedaquiline administration.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hughes JA, Solans BP, Draper HR, et al. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. Clin Infect Dis. 2022. PMID: 35377434. doi:10.1093/cid/ciac252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。